Portfolio
As of July 29st, 2023
Click on project to learn more
Preclinical Launched after the development of the prototype, preclinical development includes a series of studies and operations aimed at confirming the product's viability, testing its safety and establishing the scientific bases and regulatory strategy necessary for all applications for clinical trial approval.
mdc-TTG
Covid-19
Ivermectin
mdc-GRT
Organ Transplant
Tacrolimus
mdc-WWM
Contraception
Progestin (non-MPA)
mdc-STM
Malaria
Ivermectin
mdc-IRM
Neuroscience
Risperidone
Clinical phase 1-2 Phase 1 includes healthy volunteers to assess their tolerance to the treatment. Phase 2 is carried with a limited group of sick patients to assess the treatment's efficacy, the drug's optimal dose and any side effects.
Clinical phase 3 Phase 3 is undertaken with a large number of sick patients to compare the treatment's efficacy to that of a placebo or a standard of care. If successful, this is the final step before the filing for marketing authorization.
mdc-TJK
Schizophrenia
Olanzapine
mdc-CWM
Post-op pain
Celecoxib
Market Once all the stages of development and approval have been received by the health authorities, the product is marketed.
mdc-IRM / UZEDY
Schizophrenia
Risperidone
In partnership with Teva Pharmaceuticals
In partnership with AIC
Internal programs
Supported by the Bill & Melinda Gates Foundation
Supported by Unitaid
Portfolio extension
We have designed a structured approach to identify new opportunities and enlarge our portfolio of proprietary and partnered products. This assessment process aims to identify unmet needs in a large panel of indications that could be met with long acting injectable treatments and identify the most compatible APIs with our technology. This preliminary step is essential to significantly increase the likelihood of success for each product entering formulation stage.